“`html
PTC Therapeutics Inc (Symbol: PTCT) shares have surpassed the average analyst 12-month target price of $54.17, trading at $55.13. There are 12 analysts contributing to this target, with estimates ranging from a low of $35.00 to a high of $75.00, indicating a standard deviation of $12.327.
As of now, the analyst ratings for PTCT include 6 strong buy, 1 buy, 4 hold, 1 sell, and 1 strong sell, with an average rating of 2.23 (where 1 is Strong Buy and 5 is Strong Sell). Investors are prompted to assess whether the current price is a temporary peak or if further increases are anticipated.
“`
